In one paragraphArticle in Circulation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
10 authors.
Brian Yu *Stanford Cardiovascular Institute, School of Medicine (B.Y., L.R., Y.L., C.T., A.K., Y.D., R.V., M.S., S.R.Z., J.C.W.), Stanford University, CA.ORCID 0000-0001-5250-1892 Lu Ren *Stanford Cardiovascular Institute, School of Medicine (B.Y., L.R., Y.L., C.T., A.K., Y.D., R.V., M.S., S.R.Z., J.C.W.), Stanford University, CA.ORCID 0000-0002-9731-8562 Yu LiuStanford Cardiovascular Institute, School of Medicine (B.Y., L.R., Y.L., C.T., A.K., Y.D., R.V., M.S., S.R.Z., J.C.W.), Stanford University, CA.
Chengyi TuStanford Cardiovascular Institute, School of Medicine (B.Y., L.R., Y.L., C.T., A.K., Y.D., R.V., M.S., S.R.Z., J.C.W.), Stanford University, CA.
Ana KojicStanford Cardiovascular Institute, School of Medicine (B.Y., L.R., Y.L., C.T., A.K., Y.D., R.V., M.S., S.R.Z., J.C.W.), Stanford University, CA.ORCID 0000-0002-1829-9990 Yuanyuan DaiStanford Cardiovascular Institute, School of Medicine (B.Y., L.R., Y.L., C.T., A.K., Y.D., R.V., M.S., S.R.Z., J.C.W.), Stanford University, CA.
Ravichandra VenkateshappaStanford Cardiovascular Institute, School of Medicine (B.Y., L.R., Y.L., C.T., A.K., Y.D., R.V., M.S., S.R.Z., J.C.W.), Stanford University, CA.ORCID 0000-0001-6510-380X Mengcheng ShenStanford Cardiovascular Institute, School of Medicine (B.Y., L.R., Y.L., C.T., A.K., Y.D., R.V., M.S., S.R.Z., J.C.W.), Stanford University, CA.ORCID 0000-0001-7037-6159 Shane R ZhaoStanford Cardiovascular Institute, School of Medicine (B.Y., L.R., Y.L., C.T., A.K., Y.D., R.V., M.S., S.R.Z., J.C.W.), Stanford University, CA.ORCID 0000-0002-2137-5536 Joseph C WuStanford Cardiovascular Institute, School of Medicine (B.Y., L.R., Y.L., C.T., A.K., Y.D., R.V., M.S., S.R.Z., J.C.W.), Stanford University, CA.ORCID 0000-0002-6068-8041 Funding
Elucidating Mechanism of Cardiac Fibrosis with Cell Village of Pooled Human iPSCsR01HL130020 · NHLBI · STANFORD UNIVERSITY · PI Ronglih Liao, MARK MERCOLA · 2016 to 2026
$7.3MSingle Cell Sequencing of Human iPSC-CM Subtype Identity and FunctionR01HL145676 · NHLBI · STANFORD UNIVERSITY · PI MARK MERCOLA, Joseph C. Wu · 2019 to 2026
$5.1MAssessing Effects of Microgravity on Cardiovascular Aging with AI and 3D OrganoidsUG3TR005845 · NCATS · STANFORD UNIVERSITY · PI BEHESHTI, AFSHIN, WU, JOSEPH C. · 2025 to 2025
$3.2MAdvancing Personalized Cardiac Organoids - Converging In Vitro, In Chemico, and In Silico ModelsUM1TR006031 · NCATS · STANFORD UNIVERSITY · PI Afshin Beheshti, Sarah C Heilshorn · 2026 to 2026
$3.1MAI-driven Drug Discovery Targeting Cardiac Fibrosis in Aging HeartUG3AG097135 · NIA · STANFORD UNIVERSITY · PI SAYED, NAZISH, WU, JOSEPH C. · 2025 to 2025
$900kElucidating anti-angiogenic tyrosine kinase inhibitor-induced vascular dysfunctionR00HL166693 · NHLBI · WASHINGTON UNIVERSITY · PI Mengcheng Shen · 2025 to 2026
$498kTachycardia-induced Metabolic Remodeling Drives Cardiac DysfunctionK99HL164962 · NHLBI · STANFORD UNIVERSITY · PI TU, CHENGYI · 2023 to 2024
$303kMechanisms of Tyrosine Kinase Inhibitor-induced Sinoatrial Node DysfunctionK99HL179374 · NHLBI · STANFORD UNIVERSITY · PI Lu Ren · 2026 to 2026
$153kNCATS NIH HHS UG3 TR005845NCATS NIH HHS UM1 TR006031NHLBI NIH HHS K99 HL164962NHLBI NIH HHS K99 HL179374NHLBI NIH HHS R00 HL166693NHLBI NIH HHS R01 HL130020NHLBI NIH HHS R01 HL145676NIA NIH HHS UG3 AG097135
6 · The paper itselfAbstract
PubMed holds no abstract for this paper.
Indexed as
diastoleheart failure, diastolicinduced pluripotent stem cellsmyocytes, cardiacorganoids
Identifiers
PMID42804568
PMCPMC13623075
What OpenQuestion holds
Textmetadata
Read underepoch 390